Combination therapy with antibody‑drug conjugate RC48 (disitamab vedotin) and zimberelimab (PD‑1 inhibitor) successfully controlled recurrent HER2‑positive breast cancer resistant to trastuzumab emtansine: A case report

Fan,Shanmin; He,Lianxiang; Sang,Die

doi:10.3892/ol.2023.13945

Combination therapy with antibody‑drug conjugate RC48 (disitamab vedotin) and zimberelimab (PD‑1 inhibitor) successfully controlled recurrent HER2‑positive breast cancer resistant to trastuzumab emtansine: A case report

Authors:
- Shanmin Fan
- Lianxiang He
- Die Sang
View Affiliations

Affiliations: Department of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Beijing 100122, P.R. China, Medical Affairs Department, Guangzhou Gloria Bioscience Co., Ltd., Beijing 100005, P.R. China
Published online on: July 5, 2023 https://doi.org/10.3892/ol.2023.13945
Article Number: 359
Copyright : © Fan et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Options for later‑line therapy are limited for patients with human epidermal growth factor receptor 2 (HER2)‑positive breast cancer who have exhibited resistance to several systemic treatments. Antibody drug conjugates (ADCs) and immune checkpoint inhibitors are novel approaches for HER2‑positive breast cancer, but few reports have been published regarding the efficacy of their combinations, particularly in patients with prior ADC failure. The present report describes a case of recurrent metastatic HER2‑positive breast cancer, which responded poorly to several perioperative systemic therapies, including chemotherapies, HER2‑targeted antibodies, small molecule inhibitors and trastuzumab emtansine (an ADC), along with post‑surgical radiotherapy. Following failure of front‑line therapies for recurrent cancer located in the chest wall, combination treatment with another HER2‑targeted ADC, disitamab vedotin (120 mg), and zimberelimab (240 mg), a fully humanized anti‑programmed cell death protein‑1 (PD‑1) antibody, administered intravenously every 2 weeks, was initiated. The tumor lesions improved slightly after two cycles of treatment and shrunk markedly, and almost disappeared at the end of the sixth cycle of therapy. The patient is still in remission at present. The present findings suggest the potential efficacy of HER2‑targeted ADCs combined with PD‑1 inhibitors for patients with HER2‑positive breast cancer, including those resistant to prior HER2‑targeted ADCs.

View Figures

View References

1	Siddiqui T, Rani P, Ashraf T and Ellahi A: Enhertu (Fam-trastuzumab-deruxtecan-nxki)-Revolutionizing treatment paradigm for HER2-low breast cancer. Ann Med Surg (Lond). 82:1046652022. View Article : Google Scholar : PubMed/NCBI
2	Ferraro E, Drago JZ and Modi S: Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: State of the art and future directions. Breast Cancer Res. 23:84–94. 2021. View Article : Google Scholar : PubMed/NCBI
3	Shi F, Liu Y, Zhou X, Shen P, Xue R and Zhang M: Disitamab vedotin: A novel antibody-drug conjugates for cancer therapy. Drug Deliv. 29:1335–1344. 2022. View Article : Google Scholar : PubMed/NCBI
4	Xu B, Wang J, Fang J, Chen X, Han Y, Li Q, Zhang P, Yuan P, Ma F, Luo Y, et al: Abstract PD4-06: Early clinical development of RC48-ADC in patients with HER2 positive metastatic breast cancer. Cancer Res. 80:PD4–06-PD04-06. 2020. View Article : Google Scholar : PubMed/NCBI
5	Wang J, Liu Y, Zhang Q, Feng J, Fang J, Chen X, Han Y, Li Q, Zhang P, Yuan P, et al: RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies. J Clin Oncol. 39:1022. 2021. View Article : Google Scholar : PubMed/NCBI
6	Wu Q, Qian W, Sun X and Jiang S: Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. J Hematol Oncol. 15:143–205. 2022. View Article : Google Scholar : PubMed/NCBI
7	National Comprehensive Cancer Network (NCCN), . NCCN Clinical Practice Guidelines in Oncology Breast Cancer. Version 4. NCCN; Plymouth Meeting, PN: 2023, View Article : Google Scholar : PubMed/NCBI
8	Liu D, Ma C, Lu P, Gong J, Ye D, Wang S, Peng P, Bai Y, Song Y, Chen J, et al: Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma. Eur J Cancer. 148:1–13. 2021. View Article : Google Scholar : PubMed/NCBI
9	Lin N, Zhang M, Bai H, Liu H, Cui J, Ke X, Zhang H, Liu L, Yan D, Jiang Y, et al: Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study. Eur J Cancer. 164:117–126. 2022. View Article : Google Scholar : PubMed/NCBI
10	Markham A: Zimberelimab: First approval. Drugs. 81:2063–2068. 2021. View Article : Google Scholar : PubMed/NCBI
11	Wu X, Xia L, Zhou Q, Zhu J, Wang K, Chen J, Huang Y, Kurb G, Chang B, Zhao W, et al: GLS-010 (Zimberelimab), a novel fully human anti-PD-1 mAb in Chinese patients with recurrent metastatic cervical cancer results from a multicenter, open-label, single-arm phase II trial. Int J Gynecol Cancer. 30:A1472020. View Article : Google Scholar : PubMed/NCBI
12	Chung HC, Ros W, Delord JP, Perets P, Italiano A, Shapira-Frommer R, Manzuk L, Piha-Paul SA, Xu L, Zeigenfuss S, et al: Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer results from the phase II KEYNOTE-158 study. J Clin Oncol. 37:1470–1478. 2019. View Article : Google Scholar : PubMed/NCBI
13	National Health Commission Of The People's Republic Of China, . Chinese guidelines for diagnosis and treatment of breast cancer 2018 (English version). Chin J Cancer Res. 31:259–277. 2019. View Article : Google Scholar : PubMed/NCBI
14	Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, et al: Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 38:1346–1366. 2020. View Article : Google Scholar : PubMed/NCBI
15	Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, et al: Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update. J Clin Oncol. 36:2105–2122. 2018. View Article : Google Scholar : PubMed/NCBI
16	Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brirley JD, Gaspar LE, Schilsky RL, Balch CM, et al: AJCC Cancer Staging Manual. 8th edition. Springer; New York, NY: pp. 589–636. 2017, View Article : Google Scholar : PubMed/NCBI
17	Ignatov T, Gorbunow F, Eggemann H, Ortmann O and Ignatov A: Loss of HER2 after HER2-targeted treatment. Breast Cancer Res Treat. 175:401–408. 2019. View Article : Google Scholar : PubMed/NCBI
18	Branco FP, Machado D, Silva FF, André S, Catarino A, Madureira R, Pinto JM, Godinho JP, Simões PD, Brito M, Casa-Nova M, Moreira AR and Passos-Coelho JL: Loss of HER2 amplification and disease prognosis after neoadjuvant treatment of HER2 amplified breast cancer. Eur J Cancer. 92:S942018. View Article : Google Scholar : PubMed/NCBI
19	Niikura N, Tomotaki A, Miyata H, Iwamoto T, Kawai M, Anan K, Hayashi N, Aogi K, Ishida T, Masuoka H, et al: Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry. Ann Oncol. 27:480–487. 2016. View Article : Google Scholar : PubMed/NCBI
20	Niikura N, Liu J, Hayashi N, Mittendorf EA, Gong Y, Palla SL, Tokuda Y, Gonzalez-Angulo AM, Hortobagyi GN and Ueno NT: Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol. 30:593–599. 2012. View Article : Google Scholar : PubMed/NCBI
21	Mittendorf EA, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt KK, Dawood S, Esteva FJ, Buzdar AU, Chen H, Eksambi S, et al: Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res. 15:7381–7388. 2009. View Article : Google Scholar : PubMed/NCBI
22	Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, Moreno-Aspitia A, Doi T, Sagara Y, Redfern C, et al: Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: Results from a phase Ib Study. J Clin Oncol. 38:1887–1896. 2020. View Article : Google Scholar : PubMed/NCBI
23	Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, et al: Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 387:9–20. 2022. View Article : Google Scholar : PubMed/NCBI
24	Jiang Z, Li J, Chen J, Liu Y, Wang K, Nie J, Wang X, Hao C, Yin Y, Wang S, et al: Chinese society of clinical oncology (CSCO) breast cancer guidelines 2022. Transl Breast Cancer Res. 3:13–40. 2022. View Article : Google Scholar : PubMed/NCBI
25	National Comprehensive Cancer Network (NCCN), . NCCN Clinical Practice Guidelines in Oncology Breast Cancer. Version 8. NCCN; Plymouth Meeting, PN: 2021, View Article : Google Scholar : PubMed/NCBI
26	von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, et al: Trastuzumab Emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 380:617–628. 2019. View Article : Google Scholar : PubMed/NCBI
27	Li L, Xu MZ, Wang L, Jiang J, Dong LH, Chen F, Dong K and Song HF: Conjugating MMAE to a novel anti-HER2 antibody for selective targeted delivery. Eur Rev Med Pharmacol Sci. 24:12929–12937. 2020. View Article : Google Scholar : PubMed/NCBI
28	Rinnerthaler G, Gampenrieder SP and Greil R: HER2 directed antibody-drug-conjugates beyond T-DM1 in breast cancer. Int J Mol Sci. 20:11152019. View Article : Google Scholar : PubMed/NCBI
29	Li L, Zhang D, Liu B, Lv D, Zhai J, Guan X, Yi Z and Ma F: Antibody-drug conjugates in HER2-positive breast cancer. Chin Med J (Engl). 135:261–267. 2021. View Article : Google Scholar : PubMed/NCBI
30	Muller P, Kreuzaler M, Khan T, Thommen DS, Martin K, Glatz K, Savic S, Harbeck N, Nitz U, Gluz O, et al: Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci Transl Med. 7:315ra1882015. View Article : Google Scholar : PubMed/NCBI
31	Iwata TN, Ishii C, Ishida S, Ogitani Y, Wada T and Agatsuma T: A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model. Mol Cancer Ther. 17:1494–1503. 2018. View Article : Google Scholar : PubMed/NCBI
32	Huang L, Wang R, Xie K, Zhang J, Tao F, Pi C, Feng Y, Gu H and Fang J: A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation. Breast Cancer Res Treat. 191:51–61. 2022. View Article : Google Scholar : PubMed/NCBI
33	Yang T, Kang L, Li D and Song Y: Immunotherapy for HER-2 positive breast cancer. Front Oncol. 13:10979832023. View Article : Google Scholar : PubMed/NCBI
34	Emens LA, Esteva FJ, Beresford M, Saura C, De Laurentiis M, Kim SB, Im SA, Wang Y, Salgado R, Mani A, et al: Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): A phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 21:1283–1295. 2020. View Article : Google Scholar : PubMed/NCBI